Articles

SWOG: Two Hormonal Agents Extend Survival over Anastrozole Alone in Metastatic Breast Cancer
By Caroline Helwick
CTRC-AACR SABCS Annual Meeting
December 2011, Vol 2, No 7
;Two antiestrogen agents may be better than one in the treatment of metastatic hormone receptor-positive breast cancer patients, according to a study conducted by the Southwest Oncology Group (SWOG) clinical trials network and presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.
Read More
FDA Revokes Bevacizumab’s Breast Cancer Indication
FDA Approvals, News & Updates
December 2011, Vol 2, No 7
The FDA has revoked its previous accelerated (and conditional) approval for bevacizumab (Avastin, Genentech) for the treatment of metastatic breast cancer (MBC), citing safety concerns that outweigh its benefits in this patient population.
Read More
5-Year Analysis of VISTA Confirms Survival Advantage with Bortezomib for Patients with Myeloma
By Audrey Andrews
ASH 2013 Annual Meeting
December 2011, Vol 2, No 7
Patients with multiple myeloma receiving bortezomib (Velcade) in the pivotal VISTA trial lived more than 1 year longer than those in the control group, according to the final, 5-year analysis of the study presented at the 2011American Society of Hematology annual meeting.
Read More

Page 303 of 329

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.